At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ⅱ Study of Chiauranib Plus Albumin-paclitaxel and Gemcitabine as First-line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Chiauranib, Albumin-paclitaxel Injection, and 1 other intervention for Pancreatic Ductal Adenocarcinoma. Active but no longer recruiting, targeting 42 participants across 1 site.
Signals
Detailed Summary
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Study Details
Timeline
Interventions
Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily
Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle